Charles River Laboratories Intl. Inc vs Godaddy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Godaddy Inc trades at $104.37 (market cap $13.07B). The key difference: Charles River Laboratories Intl. Inc and Godaddy Inc are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Godaddy Inc for 64 Days on average.
| CRL | GDDY | |
|---|---|---|
Market Cap | $14.23B | $13.07B |
Volume | 1,176,885 | 1,831,274 |
Sector | Health | Technology |
52-Week High | $310.77 | $135.18 |
52-Week Low | $149.93 | $75.07 |
Typical Hold Time | 33 Days | 64 Days |
Enterprise Value | $17.06B | $15.75B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
GoDaddy (GDDY) trades at $103.19, up 6.15% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $4.95B revenue, 17.83% net margin, and consistent earnings beats in recent quarters. However, the stock faces headwinds from multiple securities class action lawsuits alleging misrepresentation of domain contract terms during September 2025-February 2026 period, creating significant legal overhang despite positive operational performance.
While GoDaddy maintains strong profitability and analyst support (58% buy ratings), the legal challenges present substantial near-term risk. The stock trades above consensus price target of $96.20, suggesting limited upside potential. Investors must weigh robust financial performance against litigation uncertainties that could impact shareholder value through settlements or reputational damage.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →